Method 1: Indocyanine green dye
DrugInjection 4 mL of ICG dye directly into the fallopian tube (1 or more places is acceptable) only to the side where the adnexal mass is located
Other names: ICG dye
NCT Number: NCT04051502
The purpose of this study is to find out how well ovarian sentinel lymph nodes (SLNs) can be identified with indocyanine green (ICG) dye during risk-reducing ovarian surgery.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Early Phase 1
Memorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
°For this protocol, "suspected high stage disease" will be defined as any patient with radiologic or clinical evidence of ovarian cancer which has spread outside of the ovary. Thus, only patients with an adnexal mass, or bilateral adnexal masses, are eligible.
Exclusion criteria
Injection 4 mL of ICG dye directly into the fallopian tube (1 or more places is acceptable) only to the side where the adnexal mass is located
Other names: ICG dye
1mL of ICG injected at each of the four sites: only to the side where the adnexal mass is located
Other names: ICG dye
Injection of 2mL of ICG dye into the IP ligament pedicle after the adnexal mass has been removed. Only to the side where the adnexal mass is located
Other names: ICG dye
Time frame: 1 year
Evaluate for dye uptake in the regional lymphatic channels, and in the pelvic and para-aortic nodes using infrared imaging.
Memorial Sloan Kettering Cancer Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03837327
Adnexal Diseases, Adnexal Mass
Los Angeles, California, United States
View Trial DetailsNCT03593681
Abdominal Neoplasms, Adnexal Diseases
San Diego, California, United States
View Trial DetailsNCT00987649
Adnexal Diseases, Adnexal Mass
San Diego, California, United States
View Trial DetailsNCT05051722
Adnexal Diseases, Adnexal Mass
Phoenix, Arizona, United States
View Trial Details